Speaker Profile
Biography
Marco Quarta is a scientist, entrepreneur, and biotechnology executive dedicated to advancing the science of aging and regenerative medicine. He is the founding Chief Executive Officer and current Chief Scientific Officer of Rubedo Life Sciences, a company pioneering new classes of therapeutics designed to selectively target senescent cells and other key mechanisms of age-related disease.
From 2008 to 2018, Dr. Quarta was a leading scientist at Stanford University, where he directed research and development at the Center for Tissue Regeneration, Repair, and Restoration of the VA Hospital in Palo Alto, in collaboration with the Stanford School of Medicine. At Stanford, he built and led a translational program in regenerative medicine, bridging discoveries in stem cell biology and tissue repair with clinical applications in aging and chronic disease.
He has authored more than 40 peer-reviewed publications and patents spanning aging biology, stem cells, regenerative medicine, and cellular rejuvenation. Dr. Quarta has also played a key role in biotechnology entrepreneurship, co-founding Turn Biotechnologies, Wetware Concepts, and YEBN, and serving on the Executive Board of the European Federation of Biotechnology.
Currently, Dr. Quarta is a member of the Paul F. Glenn Center for the Biology of Aging Studies at Stanford University, serves on the Advisory Board of the California Institute for Regenerative Medicine (CIRM) Cal Poly Bridge Program, and on the Advisory Board of the Center for Healthcare Innovation. He is also the President and co-founder of the Phaedon Institute, a non-profit scientific organization dedicated to advancing Longevity Medicine, fostering dialogue between academia, industry, and healthcare systems on the future of aging therapeutics.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Michael Goldman, SFSU
PMWC Award Ceremony
• David Sinclair, Harvard
• Steve Horvath, Altos Labs
• Nir Barzilai, Albert Einstein College of Medicine
AI-Driven Biomarkers to Quantify Aging
• Chair: Alex Zhavoronkov, Insilico Medicine
• Mahdi Moqri, Harvard
• Steve Horvath, Altos Labs
• Hussain Ahamed, Ultrahuman
Epigenetic Aging Signatures in Large Human Cohorts
• Varun Dwaraka, TruDiagnostic
AI Systems for Personalized Longevity: How Biomarkers Translate into Actionable Interventions
• Chair: Nathan Price, Buck Institute
• Sherry Zhang, Buck Institute
• Ranjan Sinha, Digbi Health
• Zeenia Framroze, Alethios, Inc.
Telomere Extension Clinical Trials Under LARTA/FDA
• John Ramunas, Rejuvenation Technologies
Clinical Trial Design & Functional Endpoints for Healthspan
• Nir Barzilai, Albert Einstein College of Mediciney
The data We Need For AI To Accelerate Longevity Drugs
• Martin Jensen, Gordian Biotechnology
From Genome to an AI-Drive Longevity Platform
• Wei-Wu He, Human Longevity
Wellness Wearables: The Journey to Clinical
• Hussain Ahamed, Ultrahuman
Longevity Medicine: Ambition vs Evidence in the Era of Precision Health
• Aubrey de Grey, LEV Foundation
Precision Aging & Longevity Focused on Limited Lifespan Evidence, Vanishing Blue Zones, and Payer ROI
• S. Jay Olshansky, University of Illinois
Evolutionary perspectives on human lifespan and healthspan
• Michael Gurven, UC Santa Barbara